Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Symbotic Inc (SYM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Symbotic Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Symbotic Inc trades at $43.64 (market cap $5.55B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 7.2× Symbotic Inc's market cap. Which is the better fit depends on your goals.
| ALNY | SYM | |
|---|---|---|
Market Cap | $39.89B | $5.55B |
Sector | Health | Technology |
52-Week High | $491.22 | $87.30 |
52-Week Low | $278.09 | $38.57 |
Enterprise Value | $38.15B | $3.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SYM trades at $43.64, up 1.14% with neutral technical signals. The company reported $2.25B revenue in 2025 but a net loss of $16.94M, though margins are improving. Recent acquisition of ARMS Innovations expands warehouse automation capabilities. Analyst consensus is bullish with a $57.50 price target, representing 32% upside potential from current levels.
Outlook remains positive due to strong revenue growth and expanding automation market, but profitability challenges and competitive pressures present risks. The stock offers growth potential but requires monitoring of earnings trajectory and market position in the evolving robotics sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
